Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen
Sign Up to like & getrecommendations! Published in 2024 at "Nature Communications"
DOI: 10.1038/s41467-024-50781-4
Abstract: TBI-223, a novel oxazolidinone for tuberculosis, is designed to provide improved efficacy and safety compared to linezolid in combination with bedaquiline and pretomanid (BPaL). We aim to optimize the dosing of TBI-223 within the BPaL… read more here.
Keywords: enhanced therapeutic; tbi 223; optimization tbi; compared linezolid ... See more keywords